'challenges for a GP and medical columnist

Slides:



Advertisements
Similar presentations
Thoughts on the Use of Decision Analysis in the Review of New Drug Applications October 3, 2007 Todd Durham.
Advertisements

Matt Downton Workplace Health Specialist Welsh Assembly Government
May 2005 CHD Health Equity Audit PRIMIS Fifth Annual Conference 11 – 12 May 2005 Piecing Together the Future Vicky Smith Jane Robinson.
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Heart Failure Diagnosis and Management in Primary Care Dr David Ebbs GP, Didcot Health Centre GPwSI Heart Failure, OxonPCT.
Presentation title: 32pt Arial Regular, black Recommended maximum length: 1 line International efforts to improve quality, reduce costs and increase transparency.
Greenspace and Wellbeing event 13 February 2008 Dr William Bird Strategic Health Advisor Natural England.
National Service Frameworks Dr Stephen Newell February 2002.
©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
“ Handle with Care” A GP guide to cancer care for elderly patients.
Prostate Cancer Support Federation Charity Nº: We have no national screening programme for the most common cancer in men and the only test we.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
Nicola Barnstaple Programme Manager. Key challenges in Scotland Increasing cancer incidence – predicted 35,000 cases per year in 2020 Ageing population.
Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!
Prepare for Personalized Medicine Family Health History – An important first step in risk assessment for genetic diseases and other hereditary health conditions.
The Healthy Option Is that the Route to Funding? Sport and Recreation Alliance Annual Conference 4 th May 2011 Dr William Bird MBE GP Intelligent Health.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Extension Article by Dr Tim Kenny
ABCWINRisk and Statistics1 Risk and Statistics Risk Assessment in Clinical Decision Making Ulrich Mansmann Medical Statistics Branch University of Heidelberg.
U.K. watchdog rejects new skin cancer drug Maria Cheng/ Associated Press
Few more cases Cancer and cholesterol. Cancer and genetic testing Available guidance (NICE) Familial breast cancer /colonic/ovarian Familial Hypercholesteremia.
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
Hypertension (high blood pressure) Dr. Fiona Gillan GP Registrar at Church End Medical Centre.
How You Can Be an Advocate for Clinical Trials in Your Community.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Survivorship after Breast Cancer Michelle Derbyshire Macmillan Breast Care Nurse Sunderland Royal Hospital February 2012.
CERVICAL CANCER: EARLY DETECTION, DIAGNOSIS & TREATMENT in LRS By Dr D. A. Kombe, MD, Mmed (Rad/onc) 2 nd East Africa WE CAN Breast & Cacx Advocacy, Education.
Healthcare in the UK Margaret Costello – Gorlin Syndrome Group.
Population Impact Measures (PIM)
Multiple Choice Questions for discussion
Cervical Sample Taker Training 2015 THE NHS CERVICAL SCREENING PROGRAMME (NHSCSP)
Risk estimation and the prevention of cardiovascular disease SIGN 97.
*To Err is Human: Building a Safer Health System. National Academy Press, 2001 Why is DynaMed Needed? Between 44,000 and 98,000 American deaths per year.
Incentives for Medical Practice Transformation: The Bridges to Excellence Initiatives A. O’tayo Lalude, MD Louisville, Kentucky at The Third Annual HIT.
What do patients want from healthcare? Professor David Haslam CBE Chair, NICE Responsible Officers Conference, Brighton.
IMPROVING DIABETES MANAGEMENT IN PRIMARY CARE
Chapter 1. Chapter 2 Dr Spock 1956 edition switches his recommendation to face down USA Second study Suggests harm First.
Healthcare rationing is used by health insurers, the government and individuals to save money. Most of us believe that if there is a treatment available,
PERIODIC MEDICAL EXAMINATION BY DR. ANGELA ESOIMEME MBBS, MPH, FWACGP.
Dr K N Prasad Community Medicine
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
Biomedical Vs Preventative Health Care. Preventative Health Care Involves taking action to avoid illness occurring or returning and to detect illness.
Joel T Nowak, M.A., M.S.W. Director of Advocacy & Advanced Prostate Cancer Programs for Malecare Survivor of four cancers including Thyroid, Kidney, Melanoma.
Equal Treatment: Closing the gap Final results. Why we investigated ‘Far too many people…are dying in their 40s, 50s or even younger – far more than in.
Health Checks. Introductions Today’s Layout 14:00 – 14:30 Welcome and Introductions Update from Hospital Discharges Slot for any updates from Go To people.
Rationalizing the New Healthcare Paradigm Scientific Agenda vs. Patient Imperatives Scientific Agenda vs. Patient Imperatives.
NATIONAL INITIATIVES: BEST PRACTICE AND LESSONS LEARNED FROM SCOTTISH EXPERIENCE Alan MacDonald Vice Chairman Scottish Medicines Consortium Hard Choices.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
Models/ Health Experts
Screening 15. May BMJ 2003; 327: ”To ask about the ethics of screening, generally aimed to make healthier people healthier, sounds, if.
Putting Patients at the Centre of Care What can my Community Pharmacist do for me? Dr Tarlochan Gill Chairman, Kent & Medway Pharmacy Local Professional.
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Discussing numerical data with patients. Framing Framing manipulations: describing equivalent choice situations in different ways Information on relative.
The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
What are the Chances Dr? Nick Pendleton. Can I have a Prostate Check? ?
Suicide and self-harm in people with bipolar disorder Better Care for People with Bipolar Disorder Manchester January 2015 Nav Kapur The Centre for Suicide.
Chapter 7: Epidemiology of Chronic Diseases. “The Change You Like to See….” (1 of 3) Chronic diseases result from prolongation of acute illness. – With.
Early Intervention in Dementia Bernie Coope Consultant Old Age Psychiatrist/Associate Medical Director/Honorary Senior Lecturer, Worcester Association.
Critical Appraisal II Prepared by Dr. Hoda Abd El Azim.
Communicating Risk.
Hypertension November 2016
You’ve Got the Power! What African Americans Should Know About Clinical Trials National Medical Association.
Prescribing.
Who Am I? Doctor Paediatrician Medicines Research
Diagnosis of disease M2/D2
LRC-CPPT and MRFIT Content Points:
Hypertension November 2016
Presentation transcript:

'challenges for a GP and medical columnist

My shared challenges Helping people access fair information Accurate information Challenging poor evidence/assumption, useful choice Being independent ….Avoiding libel

Making our minds up In an information market, who do we trust to give us fair information about health? Doctors/health professionals Charities/lay people Media outlets, journalists, the internet/bloggers PR industry Pharmaceutical companies Researchers and journals

Who is truly independent? The benefits of breast screening far outweigh the risks and I would strongly encourage all women to make an informed choice to attend for screening when invited Julietta Patnick, director of NHS Cancer Screening Programmes over diagnosis is fact

What would be more useful information? Number needed to screen Rate of false positives and negatives Implications of these Standard NHS information 1 in 9 women will get breast cancer at some point in their life 1 in 20 recalled No NNS/absolute risks used

Systematic review, Nordic Cochrane Centre, ,000 women over 10 years one would have her life prolonged 10 would endure potentially unnecessary treatment for breast cancer Another 200 of those women would have "false positive" results

Herceptin dont let my mum die - Telegraph Instant cure-all Once in a decade, a drug comes along that represents a real medical advance, and when it does we must grasp the chance to use it. The Observer, Leader, May 22 nd 05 remember there is still another key step that Herceptin has to go through, which is the NICE and the SMC approval processes for use of Herceptin by the NHS…hopes that NICE and the SMC will approve the use of Herceptin quickly Breast Cancer Campaign

Breast Cancer Action Group of Australia we deplore the situation in which it appears that women are being provided with information which is not adequately balanced via the media and some clinicians as well as the lack of generally balanced information. No industry funding, entirely independent

What would be more useful? per cent of women have HER-2 positive breast cancer The HER-2 test is only 80 per cent accurate two years worth of data in 2005; HERA trial 77.4 %of patients were disease-free and alive. If Herceptin was used in addition, then 85.8% alive and disease-free cardiac side effects. The full analysis HERA due in 2007

Dr Jane Keidan BMJ Jan 2007 More careful analysis of the "50% benefit" which had been widely quoted in the medical and non- medical press….and fixed in my mind, actually translated into a 4-5% benefit to me, which equally balanced the cardiac risk. So I elected not to receive the drug and will be happy with this decision even if my tumour returns. This story illustrates how even a medically trained and usually rational woman becomes vulnerable when diagnosed as having a potentially life threatening illness.

The eGFR test requirement of current GP contract Patients with groups of CKD as defined by eGFR to be on ACE inhibitor No evidence base for this Inappropriate, unnecessary treatment Political, not clinical, target

A readers reaction This whole process has pissed me off totally, and raises a number of issues: I seem to have had blood samples taken which have been used for tests I had not been asked to consent to, nor was I given any advance information that they would be carried out, nor any proper initial explanation of what the results implied. I was then subjected to further medical investigations without a proper explanation of why they were necessary, apart from there apparently being a need to establish a base line for measuring future progress of any `problem' found in these investigations. I am now taking medication (at some cost to taxpayers generally as I don't pay for prescriptions) to try to prevent the remote possibility of my needing an intervention, which should I survive for long enough to need it, will probably not be available in any case.

treatment choice Statins Hypertension - all standardised and contract treatments Who are we treating? Individuals or population? GPs or public health doctors?

The Flora Lady Man aged 42 – TC:HDL ratio 6 Never smoked, no family history CVS disease Exercises regularly, BP 138/80 at least I know I thought Id need those statin tablets.. as well as changing my margarine.

Guidelines

What do I do? WOSCOPS matches population From the trial PRAVASTATIN RAPIDLY REDUCES RISK OF HEART ATTACKS AND SAVES LIVES OF PEOPLE WITH HIGH CHOLESTEROL AND NO PREVIOUS HEART ATTACK West of Scotland Coronary Prevention Study Appears in 16th November NEJM

WOSCOPS People with high cholesterol can rapidly reduce their risk of having a first-time heart attack by 31 per cent and their risk of death by 22 per cent, by taking a widely prescribed drug called pravastatin sodium. This is the conclusion of a landmark study presented today at the annual meeting of the American Heart Association. The results appear in the 16th November edition of the New England Journal of Medicine…

John-Arne Skolbekken BMJ1998; Yet another way of stating the facts would be to say that patients with angina or after a myocardial infarction may improve their probability of avoiding coronary death from 91.5% to 95% by taking simvastatin, while people without prior coronary disease may improve their probability from 98.3% to 98.8% by taking pravastatin ….

… Medicine is not an exact science. Therefore, 200 men without any prior heart disease have to swallow tablets over five years to save one of them from dying from coronary heart disease. This is due to the fact that no exact knowledge exists as to whom of these 200 will benefit from the treatment.

Side effects underestimated (20% thought to have some) -Impact on quality of life -I dont go salsa dancing any more Drop out rates from some statin studies 30% How far should a doctor recommend Rx? Do we advocate for guidelines or the patient?

What I try to do Share helpful information Discuss priorities, side effects and aims Veer off protocols Share uncertainties ….Lose control Offer advice/advocacy/lateral housekeeping perspective Holistic Care

who can be relied on to give independent, fair, and evidence based advice? Medics? Politicised/deprofessionalised/self interest Media? PR/sales/lack of science graduates Press releases? Panic or pertinant Researchers/experts? How to interpret papers/meaningfulness

A plea… NNT, absolute vs relative risks and community abstracts published as standard what will the press will make of it? and patients without the knowledge to understand it – and patients and doctors without access to full details Lots of adverse effects go unstudied